DelveInsight’s “Uterine Fibroids Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Uterine Fibroids pipeline landscape. It covers the Uterine Fibroids pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Uterine Fibroids Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Uterine Fibroids Drugs @ https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight

Key Takeaways from the Uterine Fibroids Pipeline Report

• On February 11, 2026, Shenzhen Kangzhe Biotechnology Co., Ltd. conducted a Phase II Clinical Study to Explore the Efficacy and Safety of Different Doses of CMS-D002 Capsule in Participants With Uterine Fibroids Associated With Menorrhagia.
• On February 02, 2026, Qilu Pharmaceutical Co., Ltd. conducted a study is a phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-designed efficacy and safety study to evaluate 12 weeks of oral daily relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg (the treatment group) or 12 weeks of daily oral relugolix 40 mg placebo (the placebo group) followed by 12 weeks of daily oral relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg.
• DelveInsight’s Uterine Fibroids Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline Uterine Fibroids drugs.
• The leading Uterine Fibroids Companies such as AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.
• Promising Uterine Fibroids Therapies such as Progenta, Relugolix, Estradiol, Telapristone Acetate, Leuprorelin (GF), Leuprorelin (GF), TAK-385, PGL4001 5 mg and others.

Find out more about Uterine Fibroids Drugs @ Uterine Fibroids Treatment

Uterine Fibroids Overview

Uterine fibroids are benign (not cancer) growths that develop from the muscle tissue of the uterus. They also are called leiomyomas or myomas. The size, shape, and location of fibroids can vary greatly. They may be inside the uterus, on its outer surface or within its wall, or attached to it by a stem-like structure. A woman may have only one fibroid or many of varying sizes. A fibroid may remain very small for a long time and suddenly grow rapidly, or grow slowly over a number of years. Fibroids are most common in women aged 30–40 years, but they can occur at any age. Fibroids occur more often in African American women than in white women. They also seem to occur at a younger age and grow more quickly in African American women

Uterine Fibroids Emerging Drugs

• Linzagolix: Kissei Pharmaceutical

Linzagolix is a novel, orally administered GnRH (gonadotropin releasing hormone) receptor antagonist. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately reducing estrogen production by the ovaries. It is currently in phase III stage of development.

• Relugolix: Myovant Sciences

Relugolix is a small molecule, gonadotropin-releasing hormone (GnRH) receptor antagonist, and an oral investigational drug candidate for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer. As a GnRH receptor antagonist, relugolix binds to and blocks the GnRH receptor (GnRHR) in the anterior pituitary gland.Blocking GnRH receptors decreases the release of gonadotropins – luteinizing hormone (LH) and follicle-stimulating hormone (FSH) – thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men.

• Fezolinetant: Ogeda

Fezolinetant is being investigated as a superior option to gonadotropin-releasing hormone (GnRH) products as fezolinetant reduces levels of the ovarian hormones estrogen and progesterone, but in a non-castrating manner, as would be required for the safe, effective, chronic treatment of uterine fibroids and endometriosis. It is in phase II stage of development.

The Uterine Fibroids Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Fibroids with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Fibroids Treatment.
• Uterine Fibroids Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uterine Fibroids Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Fibroids market.

Learn more about Uterine Fibroids Drugs opportunities in our groundbreaking Uterine Fibroids research and development projects @ Uterine Fibroids Unmet Needs

Uterine Fibroids Companies

AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.

Uterine Fibroids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Stay informed about how we’re transforming the future of Respiratory Disease @ Uterine Fibroids Market Drivers and Barriers, and Future Perspectives

Scope of the Uterine Fibroids Pipeline Report

• Coverage- Global
• Uterine Fibroids Companies- AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.
• Uterine Fibroidss Therapies- Progenta, Relugolix, Estradiol, Telapristone Acetate, Leuprorelin (GF), Leuprorelin (GF), TAK-385, PGL4001 5 mg and others.
• Uterine Fibroids Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Uterine Fibroids Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new Uterine Fibroids Treatments, visit @ Uterine Fibroids Drugs

Table of Contents

1. Introduction
2. Executive Summary
3. Uterine fibroids: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Uterine fibroids – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Uterine fibroids Collaboration Deals
9. Late Stage Products (Phase III and NDA)
10. Linzagolix: Kissei Pharmaceutical
11. Relugolix: Myovant Sciences
12. Mid Stage Products (Phase II)
13. Fezolinetant: Ogeda
14. Early Stage Products (Phase I)
15. Pre-clinical and Discovery Stage Products
16. Inactive Products
17. Uterine fibroids Key Companies
18. Uterine fibroids Key Products
19. Uterine fibroids- Unmet Needs
20. Uterine fibroids- Market Drivers and Barriers
21. Uterine fibroids- Future Perspectives and Conclusion
22. Uterine fibroids Analyst Views
23. Uterine fibroids Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/uterine-fibroids-pipeline-insight